Gastric Cancer Diagnosis Improved with Autoantibody Analysis

Research has identified a promising method for the early detection of gastric cancer through the analysis of autoantibodies in the blood. According to a study published in Cancer Biomarkers, a combination of IgG and IgA autoantibodies can serve as non-invasive biomarkers for gastric cancer diagnosis, distinguishing it from gastritis and other conditions. The study, conducted by Tao Wang and colleagues, analyzed serum samples from patients with gastric cancer, gastritis, and healthy controls to identify differentially expressed autoantibodies.

Key Takeaways:

• The study identified 24 differentially expressed autoantibodies (DEAs) for IgA and 17 for IgG between gastric cancer patients and controls.
• In distinguishing gastric cancer from gastritis, 20 DEAs for IgA and 23 for IgG were significant.
• The IgG/IgA ratio of MIP1 beta had the highest diagnostic performance between atrophic gastritis and gastric cancer, while MMP7 was the most effective between chronic gastritis and gastric cancer.
• A 14-autoantibody model had the highest Youden's index for gastric cancer versus controls, while a 13-autoantibody model performed best for gastric cancer versus all gastritis.
• Specific panels of autoantibodies could serve as non-invasive diagnostic tools for distinguishing gastric cancer from controls and gastritis.

Statistics:

• 27 autoantibodies were analyzed in serum from 265 healthy controls, 296 gastric cancer patients, and 195 gastritis patients.
• 24 DEAs for IgA and 17 for IgG were identified between gastric cancer patients and controls.
• 20 DEAs for IgA and 23 for IgG were significant in distinguishing gastric cancer from gastritis.
• The IgG/IgA ratio of MIP1 beta had a diagnostic performance of between atrophic gastritis and gastric cancer.
• A 14-autoantibody model had a Youden's index of for gastric cancer versus controls.

Sources:

• Tao Wang et al. (2025). Combination detection of IgG- and IgA-related autoantibodies for the early diagnosis of gastric cancer. Cancer Biomarkers, 42(10), 18758592251363414.
• Guangzhou Innovation Leadership Team, National Key R&D Program of China, Joint Funds of the National Natural Science Foundation of China, National Natural Science Foundation of China, UK-China (Guangzhou) Healthtech Open Innovation, Guangzhou 2024 Annual Agricultural and Social Development Science and Technology Special Topics.